$RAC

$RAC announces conclusion of an investigator-sponsored trial of bisantrene – Race Oncology

Race Oncology made the following post on X:

“$RAC is pleased to announce the successful conclusion of an investigator-sponsored Phase 1b/2 trial of bisantrene, with trial results showing the drug, in combination with clofarabine and fludarabine, has achieved its primary endpoint for efficacy.
More.”

Source: Race Oncology/X

$RAC bisantrene cancer cancer therapy cancer treatment clinical trial results clofarabine drug efficacy fludarabine Investigator-Sponsored trial OncoDaily Oncology oncology research Phase 1b/2 trial primary endpoint Race Oncology Research successful trial